EA201490743A1 - Фармацевтические композиции, содержащие 40-о-(2-гидрокси)этилрапамицин - Google Patents
Фармацевтические композиции, содержащие 40-о-(2-гидрокси)этилрапамицинInfo
- Publication number
- EA201490743A1 EA201490743A1 EA201490743A EA201490743A EA201490743A1 EA 201490743 A1 EA201490743 A1 EA 201490743A1 EA 201490743 A EA201490743 A EA 201490743A EA 201490743 A EA201490743 A EA 201490743A EA 201490743 A1 EA201490743 A1 EA 201490743A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- pharmaceutical compositions
- hydroxy
- dosage forms
- ethylrapamicin
- compositions containing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2893—Tablet coating processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Transplantation (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Изобретение относится к фармацевтическим составам длительного высвобождения в форме множественных частиц, содержащим 40-О-(2-гидрокси)этилрапамицин, к дозированным формам, которые содержат указанные фармацевтические составы, к способам приготовления указанных фармацевтических составов и указанных дозированных форм, к применениям указанных фармацевтических составов и указанных дозированных форм для изготовления лекарственного препарата для лечения или профилактики заболеваний или состояний, реагирующих на ингибирование mTOR сигнального пути, таких как, например, пролиферативные заболевания или иммуносупрессия.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161544026P | 2011-10-06 | 2011-10-06 | |
PCT/EP2012/069541 WO2013050419A1 (en) | 2011-10-06 | 2012-10-03 | Pharmaceutical compositions comprising 40 - o - ( 2 - hydroxy) ethyl - rapamycin |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201490743A1 true EA201490743A1 (ru) | 2014-07-30 |
EA025595B1 EA025595B1 (ru) | 2017-01-30 |
Family
ID=46968222
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201490743A EA025595B1 (ru) | 2011-10-06 | 2012-10-03 | Фармацевтические композиции, содержащие 40-о-(2-гидрокси)этилрапамицин |
Country Status (23)
Country | Link |
---|---|
US (3) | US20140242162A1 (ru) |
EP (1) | EP2763663B1 (ru) |
JP (1) | JP6368242B2 (ru) |
KR (1) | KR101643219B1 (ru) |
CN (1) | CN103874484B (ru) |
AR (1) | AR088232A1 (ru) |
AU (1) | AU2012320563B2 (ru) |
BR (1) | BR112014007902A2 (ru) |
CA (1) | CA2850995A1 (ru) |
CL (1) | CL2014000844A1 (ru) |
CO (1) | CO6930364A2 (ru) |
EA (1) | EA025595B1 (ru) |
ES (1) | ES2663744T3 (ru) |
GT (1) | GT201400062A (ru) |
IL (1) | IL231648A0 (ru) |
MA (1) | MA35513B1 (ru) |
MX (1) | MX2014004166A (ru) |
PE (1) | PE20141649A1 (ru) |
SG (1) | SG11201400730VA (ru) |
TN (1) | TN2014000114A1 (ru) |
TW (1) | TWI475993B (ru) |
WO (1) | WO2013050419A1 (ru) |
ZA (1) | ZA201401961B (ru) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201503912A (zh) * | 2013-03-19 | 2015-02-01 | Novartis Ag | 包含癌莫事(everolimus)之醫藥組合物 |
PL3193840T3 (pl) | 2014-09-15 | 2021-12-06 | Orphazyme A/S | Preparat arimoklomolu |
WO2016138505A1 (en) | 2015-02-27 | 2016-09-01 | Ebbu, LLC | Compositions comprising combinations of purified cannabinoids, with at least one flavonoid, terpene, or mineral |
CN107847491A (zh) | 2015-05-20 | 2018-03-27 | 诺华公司 | 依维莫司(everolimus)与达托里昔布(dactolisib)的医药组合 |
WO2017018433A1 (ja) * | 2015-07-28 | 2017-02-02 | 日本化薬株式会社 | ラパマイシン又はその誘導体を含有する医薬組成物及びその製造方法 |
JP6762158B2 (ja) * | 2015-07-28 | 2020-09-30 | 日本化薬株式会社 | ラパマイシン又はその誘導体を含有する医薬組成物 |
EP3345601A4 (en) * | 2015-09-03 | 2019-05-15 | Nippon Kayaku Kabushiki Kaisha | PHARMACEUTICAL COMPOSITION CONTAINING RAPAMYCIN OR A DERIVATIVE THEREOF |
JP6854639B2 (ja) * | 2016-01-06 | 2021-04-07 | 日本化薬株式会社 | ラパマイシン誘導体を含有する医薬組成物及びその製造方法 |
CN110177543A (zh) | 2016-08-29 | 2019-08-27 | 凯诺比生长公司 | 包含纯化大麻素的水溶性组合物 |
AU2017363970A1 (en) | 2016-11-23 | 2019-06-20 | Novartis Ag | Methods of enhancing immune response with everolimus, dactolisib or both |
EP3576735A4 (en) * | 2017-02-06 | 2020-07-22 | Intas Pharmaceuticals Limited | PHARMACEUTICAL COMPOSITION OF EVEROLIMUS |
KR102051806B1 (ko) * | 2018-01-12 | 2019-12-04 | 주식회사 종근당 | 에베로리무스를 포함하는 안정화된 약제학적 제제 |
US10596165B2 (en) | 2018-02-12 | 2020-03-24 | resTORbio, Inc. | Combination therapies |
MX2022012248A (es) * | 2020-03-30 | 2022-10-27 | Igia Pharmaceuticals Inc | Formulacion pediatrica de inhibidores de tirosina quinasa. |
WO2022219652A1 (en) * | 2021-04-17 | 2022-10-20 | Bdr Pharmaceuticals International Private Limited | Novel sublingual pharmaceutical formulations for everolimus |
KR102336007B1 (ko) * | 2021-06-23 | 2021-12-07 | 주식회사 진성이앤지 | 콘크리트용 우레탄계 방수·방식 도막재 및 이를 이용한 방수·방식 도장 공법 |
WO2023044024A1 (en) * | 2021-09-17 | 2023-03-23 | Novelstar Pharmaceuticals Inc. | Novel ph dependent coating drug delivery system |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5472712A (en) * | 1991-12-24 | 1995-12-05 | Euroceltique, S.A. | Controlled-release formulations coated with aqueous dispersions of ethylcellulose |
GB9221220D0 (en) | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
BE1009856A5 (fr) | 1995-07-14 | 1997-10-07 | Sandoz Sa | Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule. |
KR100440553B1 (ko) * | 1998-03-26 | 2004-07-15 | 후지사와 야꾸힝 고교 가부시키가이샤 | 서방성 제제 |
GB0123400D0 (en) | 2001-09-28 | 2001-11-21 | Novartis Ag | Organic compounds |
AR045957A1 (es) * | 2003-10-03 | 2005-11-16 | Novartis Ag | Composicion farmaceutica y combinacion |
GB0419355D0 (en) * | 2004-08-31 | 2004-09-29 | Novartis Ag | Organic compounds |
EP1902708A1 (de) * | 2006-09-25 | 2008-03-26 | Losan Pharma GmbH | Wirkstoff enthaltende stabilisierte feste Arzneimittelformen und Verfahren zu ihrer Herstellung |
EP2365802B1 (en) * | 2008-11-11 | 2017-08-02 | The Board of Regents,The University of Texas System | Microcapsules of rapamycin and use for treating cancer |
CN101862297B (zh) * | 2009-04-14 | 2012-07-25 | 上海医药工业研究院 | 一种非水溶性药物的缓释微丸、其缓释口腔崩解片及其制备方法 |
-
2012
- 2012-10-03 ES ES12766990.1T patent/ES2663744T3/es active Active
- 2012-10-03 MX MX2014004166A patent/MX2014004166A/es not_active Application Discontinuation
- 2012-10-03 CN CN201280049427.XA patent/CN103874484B/zh not_active Expired - Fee Related
- 2012-10-03 WO PCT/EP2012/069541 patent/WO2013050419A1/en active Application Filing
- 2012-10-03 EP EP12766990.1A patent/EP2763663B1/en active Active
- 2012-10-03 JP JP2014533869A patent/JP6368242B2/ja not_active Expired - Fee Related
- 2012-10-03 SG SG11201400730VA patent/SG11201400730VA/en unknown
- 2012-10-03 AU AU2012320563A patent/AU2012320563B2/en not_active Ceased
- 2012-10-03 EA EA201490743A patent/EA025595B1/ru not_active IP Right Cessation
- 2012-10-03 PE PE2014000448A patent/PE20141649A1/es not_active Application Discontinuation
- 2012-10-03 US US14/349,166 patent/US20140242162A1/en not_active Abandoned
- 2012-10-03 CA CA2850995A patent/CA2850995A1/en not_active Abandoned
- 2012-10-03 BR BR112014007902A patent/BR112014007902A2/pt not_active IP Right Cessation
- 2012-10-03 KR KR1020147008751A patent/KR101643219B1/ko active IP Right Grant
- 2012-10-04 AR ARP120103699A patent/AR088232A1/es unknown
- 2012-10-05 TW TW101137004A patent/TWI475993B/zh not_active IP Right Cessation
-
2014
- 2014-03-18 ZA ZA2014/01961A patent/ZA201401961B/en unknown
- 2014-03-18 TN TNP2014000114A patent/TN2014000114A1/en unknown
- 2014-03-20 IL IL231648A patent/IL231648A0/en unknown
- 2014-04-03 MA MA36880A patent/MA35513B1/fr unknown
- 2014-04-04 CO CO14073134A patent/CO6930364A2/es not_active Application Discontinuation
- 2014-04-04 CL CL2014000844A patent/CL2014000844A1/es unknown
- 2014-04-04 GT GT201400062A patent/GT201400062A/es unknown
-
2016
- 2016-11-07 US US15/345,498 patent/US20170049754A1/en not_active Abandoned
-
2018
- 2018-01-24 US US15/879,272 patent/US20180214424A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
PE20141649A1 (es) | 2014-11-14 |
CN103874484B (zh) | 2016-09-21 |
KR20140058670A (ko) | 2014-05-14 |
US20170049754A1 (en) | 2017-02-23 |
KR101643219B1 (ko) | 2016-07-27 |
CL2014000844A1 (es) | 2014-09-12 |
US20180214424A1 (en) | 2018-08-02 |
AU2012320563B2 (en) | 2016-05-12 |
TW201318625A (zh) | 2013-05-16 |
CO6930364A2 (es) | 2014-04-28 |
TN2014000114A1 (en) | 2015-07-01 |
AR088232A1 (es) | 2014-05-21 |
JP2014528431A (ja) | 2014-10-27 |
AU2012320563A1 (en) | 2014-04-24 |
MX2014004166A (es) | 2015-01-15 |
SG11201400730VA (en) | 2014-06-27 |
TWI475993B (zh) | 2015-03-11 |
WO2013050419A1 (en) | 2013-04-11 |
ZA201401961B (en) | 2015-11-25 |
MA35513B1 (fr) | 2014-10-02 |
EA025595B1 (ru) | 2017-01-30 |
CA2850995A1 (en) | 2013-04-11 |
IL231648A0 (en) | 2014-05-28 |
CN103874484A (zh) | 2014-06-18 |
BR112014007902A2 (pt) | 2017-04-18 |
US20140242162A1 (en) | 2014-08-28 |
ES2663744T3 (es) | 2018-04-16 |
EP2763663A1 (en) | 2014-08-13 |
GT201400062A (es) | 2015-06-02 |
EP2763663B1 (en) | 2017-12-27 |
JP6368242B2 (ja) | 2018-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201490743A1 (ru) | Фармацевтические композиции, содержащие 40-о-(2-гидрокси)этилрапамицин | |
PH12014502757B1 (en) | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases | |
IN2014MN00948A (ru) | ||
IN2014MN00987A (ru) | ||
TN2015000278A1 (en) | Autotaxin inhibitors | |
IN2014MN02049A (ru) | ||
IN2014MN00988A (ru) | ||
MX341324B (es) | Polipeptidos. | |
EA201400412A1 (ru) | ЗАМЕЩЕННЫЕ БЕНЗИЛИНДАЗОЛЫ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Bub1 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ | |
IN2014MN00986A (ru) | ||
EA201391230A1 (ru) | Соединения и композиции в качестве ингибиторов trk | |
EA201301240A1 (ru) | Полиморфная форма бензоата линаглиптина | |
MX340300B (es) | Compuestos de cromenona como inhibidores de pi 3-quinasa para el tratamiento del cancer. | |
EA201591830A1 (ru) | Фармацевтические композиции, включающие эверолимус | |
EA201790949A1 (ru) | Замещенные 2,4-диаминохинолины в качестве новых противораковых средств | |
MY166449A (en) | Pharmaceutical composition of rosuvastatin calcium | |
EA029539B8 (ru) | Фармацевтическая композиция ситаглиптина | |
PH12016501686A1 (en) | Pharmaceutical compositions of sitagliptin | |
MX362879B (es) | Usos novedosos. | |
MX2014010433A (es) | Nueva forma cristalina de sulfato de sitagliptina. | |
BR112017004580A2 (pt) | composto, composição farmacêutica, produto de combinação, uso de um composto ou sal farmaceuticamente aceitável, e, método de tratamento. | |
BR112012013199A8 (pt) | Composto, composição farmacêutica, e , uso de um composto | |
EA201171414A1 (ru) | Ингибиторы белков семейства iap | |
EA201201668A1 (ru) | Δ-кристаллическая форма аргининовой соли периндоприла, способ ее получения и содержащие ее фармацевтические композиции | |
IN2014DN03010A (ru) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG TJ TM RU |